EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zoetis's Enterprise Value is $71,220 Mil.
Zoetis's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $3,175 Mil. Therefore, Zoetis's EV-to-EBIT for today is 22.43.
The historical rank and industry rank for Zoetis's EV-to-EBIT or its related term are showing as below:
ZTS'
s EV-to-EBIT Range Over the Past 10 Years
Min: 20.58 Med: 28.15 Max: 45.24
Current: 22.43
During the past 13 years, the highest EV-to-EBIT of Zoetis was 45.24. The lowest was 20.58. And the median was 28.15.
ZTS's EV-to-EBIT is ranked worse than 63.08% of 669
companies
in the Drug Manufacturers industry
Industry Median: 17.02
vs ZTS: 22.43
The historical data trend for Zoetis's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis EV-to-EBIT Distribution
For the Drug Manufacturers industry and Healthcare sector, Zoetis's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zoetis's EV-to-EBIT falls into.
Zoetis's current Enterprise Value is $71,220 Mil.
Zoetis's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,175 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (NYSE:ZTS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zoetis's Enterprise Value for the quarter that ended in Dec. 2023 was $95,178 Mil.
Zoetis's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,175 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Zoetis's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZTS has been successfully added to your 